{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:15:53Z","timestamp":1778818553663,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003790","name":"Hiroshima University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clbc.2026.03.016","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:00:36Z","timestamp":1774465236000},"page":"75-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-9655","authenticated-orcid":false,"given":"Hideo","family":"Shigematsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Sasada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Amioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Hashizume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunari","family":"Sasada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Goda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Noma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Kawamata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Yoshiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Sueoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Emi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Itagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Kajitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihito","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.03.016_bib0001","first-page":"16","article-title":"Axillary surgery for breast cancer in 2024","author":"Heidinger","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2026.03.016_bib0002","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamasurg.2023.1772","article-title":"Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer","volume":"158","author":"Kuemmel","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.clbc.2026.03.016_bib0003","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jamaoncol.2024.0578","article-title":"Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy","volume":"10","author":"Montagna","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2026.03.016_bib0004","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamasurg.2024.5913","article-title":"De-escalation of nodal surgery in clinically node-positive breast cancer","volume":"160","author":"Cabioglu","year":"2025","journal-title":"JAMA Surg"},{"key":"10.1016\/j.clbc.2026.03.016_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cells11121857","article-title":"Pathological complete response to neoadjuvant chemoimmunotherapy for early triple-negative breast cancer: an updated meta-analysis","volume":"11","author":"Rizzo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.clbc.2026.03.016_bib0006","article-title":"Pathologic complete response achieved in early-stage HER2-positive breast cancer after neoadjuvant therapy with trastuzumab and chemotherapy vs. trastuzumab, chemotherapy, and pertuzumab: a systematic review and meta-analysis of clinical trials","volume":"15","author":"Fazal","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.clbc.2026.03.016_bib0007","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/SLA.0000000000002313","article-title":"A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy","volume":"267","author":"Kuerer","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.clbc.2026.03.016_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2020.4103","article-title":"Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer","volume":"155","author":"Tasoulis","year":"2020","journal-title":"JAMA Surg"},{"key":"10.1016\/j.clbc.2026.03.016_bib0009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4048\/jbc.2023.0265","article-title":"Omission of breast surgery in predicted pathologic complete response after neoadjuvant systemic therapy: a multicenter, single-arm, non-inferiority trial","volume":"27","author":"Jung","year":"2024","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.clbc.2026.03.016_bib0010","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaoncol.2025.0207","article-title":"Exceptional responders study, selective elimination of breast surgery for invasive breast cancer: a nonrandomized clinical trial","volume":"11","author":"Kuerer","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2026.03.016_bib0011","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","article-title":"Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery","volume":"152","author":"Tadros","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.clbc.2026.03.016_bib0012","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","article-title":"Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy","volume":"153","author":"Barron","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.clbc.2026.03.016_bib0013","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1007\/s00432-021-03763-8","article-title":"Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China","volume":"147","author":"Chen","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clbc.2026.03.016_bib0014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10549-025-07697-4","article-title":"Exploring the possibility of omitting axillary surgery in patients with clinical node-positive breast cancer achieving ypT0 after neoadjuvant chemotherapy","volume":"212","author":"Shigematsu","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2026.03.016_bib0015","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/SLA.0000000000004356","article-title":"Diagnostic performance of noninvasive imaging for assessment of axillary response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis","volume":"273","author":"Samiei","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.clbc.2026.03.016_bib0016","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/cncr.35248","article-title":"An ultrasound-based nomogram for predicting axillary node pathologic complete response after neoadjuvant chemotherapy in breast cancer: modeling and external validation","volume":"130","author":"Zheng","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2026.03.016_bib0017","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.03.016_bib0018","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.03.016_bib0019","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: american Society of Clinical Oncology\/College of American Pathologists Clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.03.016_bib0020","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Investigators, Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.03.016_bib0021","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.breast.2023.01.002","article-title":"Omission of axillary sentinel lymph node biopsy in early invasive breast cancer","volume":"67","author":"Reimer","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2026.03.016_bib0022","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jamcollsurg.2017.08.027","article-title":"MRI and prediction of pathologic complete response in the breast and axilla after neoadjuvant chemotherapy for breast cancer","volume":"225","author":"Weber","year":"2017","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.clbc.2026.03.016_bib0023","first-page":"15","article-title":"Prediction of primary tumour and axillary lymph node response to neoadjuvant chemo (targeted) therapy with dedicated breast [18F]FDG PET\/MRI in breast cancer","author":"de Mooij","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2026.03.016_bib0024","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1245\/s10434-018-6345-5","article-title":"A predictive model for axillary node pathologic complete response after neoadjuvant chemotherapy for breast cancer","volume":"25","author":"Kantor","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.03.016_bib0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40644-019-0279-4","article-title":"Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer","volume":"19","author":"Al-Hattali","year":"2019","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.clbc.2026.03.016_bib0026","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jjco\/hyaa055","article-title":"Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy","volume":"50","author":"Shigematsu","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.03.016_bib0027","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1200\/JCO.21.02439","article-title":"Intelligent vacuum-assisted biopsy to identify breast cancer patients with pathologic complete response (ypT0 and ypN0) after neoadjuvant systemic treatment for omission of breast and axillary surgery","volume":"40","author":"Pfob","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.03.016_bib0028","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.annonc.2019.10.012","article-title":"Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges","volume":"31","author":"Heil","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.03.016_bib0029","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1245\/s10434-022-12455-7","article-title":"Moving forward with omission of breast cancer surgery following neoadjuvant systemic therapy","volume":"29","author":"Kuerer","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2026.03.016_bib0030","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.03.016_bib0031","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926000480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:56:35Z","timestamp":1778817395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926000480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1526820926000480"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.03.016","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}